104 related articles for article (PubMed ID: 10319944)
1. Mutations of p53 in thyroid carcinoma with an insular component.
Takeuchi Y; Daa T; Kashima K; Yokoyama S; Nakayama I; Noguchi S
Thyroid; 1999 Apr; 9(4):377-81. PubMed ID: 10319944
[TBL] [Abstract][Full Text] [Related]
2. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
3. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
4. p53 in a thyroid follicular carcinoma with foci of poorly differentiated and anaplastic carcinoma.
Matias-Guiu X; Villanueva A; Cuatrecasas M; Capella G; De Leiva A; Prat J
Pathol Res Pract; 1996 Dec; 192(12):1242-9; discussion 1250-1. PubMed ID: 9182295
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
6. p53 gene mutations in radiation-induced thyroid cancer.
Fogelfeld L; Bauer TK; Schneider AB; Swartz JE; Zitman R
J Clin Endocrinol Metab; 1996 Aug; 81(8):3039-44. PubMed ID: 8768871
[TBL] [Abstract][Full Text] [Related]
7. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma.
Lim BH; Soong R; Grieu F; Robbins PD; House AK; Iacopetta BJ
Int J Cancer; 1996 Jun; 69(3):200-4. PubMed ID: 8682588
[TBL] [Abstract][Full Text] [Related]
8. p53 mutations in childhood thyroid tumours from Belarus and in thyroid tumours without radiation history.
Smida J; Zitzelsberger H; Kellerer AM; Lehmann L; Minkus G; Negele T; Spelsberg F; Hieber L; Demidchik EP; Lengfelder E; Bauchinger M
Int J Cancer; 1997 Dec; 73(6):802-7. PubMed ID: 9399655
[TBL] [Abstract][Full Text] [Related]
9. p53 mutations in all stages of thyroid carcinomas.
Zou M; Shi Y; Farid NR
J Clin Endocrinol Metab; 1993 Oct; 77(4):1054-8. PubMed ID: 8408453
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
[TBL] [Abstract][Full Text] [Related]
11. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
Gauchotte G; Philippe C; Lacomme S; Léotard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A
Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161
[TBL] [Abstract][Full Text] [Related]
12. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
Donghi R; Longoni A; Pilotti S; Michieli P; Della Porta G; Pierotti MA
J Clin Invest; 1993 Apr; 91(4):1753-60. PubMed ID: 8473515
[TBL] [Abstract][Full Text] [Related]
13. p53 gene mutation in thyroid carcinoma.
Ho YS; Tseng SC; Chin TY; Hsieh LL; Lin JD
Cancer Lett; 1996 May; 103(1):57-63. PubMed ID: 8616809
[TBL] [Abstract][Full Text] [Related]
14. [Relationship of p53 gene mutation with pathological characteristics and prognosis of thyroid carcinoma].
Song Y; Wang L; Huang G; Yuan S; Xiao L
Hua Xi Yi Ke Da Xue Xue Bao; 2000 Sep; 31(3):298-9, 314. PubMed ID: 12545813
[TBL] [Abstract][Full Text] [Related]
15. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
16. Lack of mutation in exon 10 of p53 gene in thyroid tumors.
Santarosa PL; Granja F; Morari EC; Leite JL; Assumpção LV; Ward LS
Rev Med Chil; 2004 Dec; 132(12):1513-6. PubMed ID: 15743163
[No Abstract] [Full Text] [Related]
17. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.
Wright PA; Lemoine NR; Goretzki PE; Wyllie FS; Bond J; Hughes C; Röher HD; Williams ED; Wynford-Thomas D
Oncogene; 1991 Sep; 6(9):1693-7. PubMed ID: 1923534
[TBL] [Abstract][Full Text] [Related]
18. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21.
Lam KY; Lo CY; Chan KW; Wan KY
Ann Surg; 2000 Mar; 231(3):329-38. PubMed ID: 10714625
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 and p53 expression in insular and in well-differentiated thyroid carcinomas with an insular pattern.
Peştereli HE; Oğüş M; Oren N; Karpuzoğlu G; Kerpuzoğlu T
Endocr Pathol; 2001; 12(3):301-5. PubMed ID: 11740051
[TBL] [Abstract][Full Text] [Related]
20. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression.
Preto A; Reis-Filho JS; Ricardo S; Soares P
Pathol Res Pract; 2002; 198(7):449-54. PubMed ID: 12234063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]